According to a public report at the 2024 American Academy of Dermatology (AAD) annual meeting, ASC40, a Fatty Acid Synthase Inhibitor for treating acne, has completed preliminary clinical trials, showing that 10 days of ASC40 treatment can significantly reduce facial sebum palmitic acid levels. This evidence concerns the gene FASN and acne.